OPTI Tag

OptiBiotix Health PLC – Final Results

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its audited results for the period ended 31 December 2019. During...

Read More

OptiBiotix Health PLC – Trading Update

OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, provides the following unaudited preliminary revenue figures and a trading, commercial, and strategic update ahead of the Group's final results for the year...

Read More

OptiBiotix Health PLC – Directorate Change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces the departure of Christina Wood as Executive Sales & Marketing Director by mutual agreement....

Read More

OptiBiotix Health PLC – Half-year Report

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces its results for the six months ended 31 May 2019....

Read More

OptiBiotix Health PLC – License agreement for LPLDL® in Japan

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseand diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a non-exclusive license agreement with Tenshindo, Co. Ltd. for the use of Lactobacillus plantarum LPLDL® ("LPLDL®") in...

Read More

OptiBiotix Health PLC – Appointment of CEO of ProBiotix Health

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the appointment of Stephen Prescott as Chief Executive Officer (CEO) of its wholly-owned subsidiary, ProBiotix Health Ltd....

Read More

OptiBiotix Health PLC – License agreement for LPLDL®

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular diseaseand diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Nutrilinea Srl. for the use of LPLDL® in a food supplement for the...

Read More